Loading
Biotricity Inc. Stock: price and insider trades · United States
Biotricity Inc.: what insiders have been doing
Every trade that managers of Biotricity Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Nothing new has been filed by managers of Biotricity Inc. in twelve months, the latest record being from 6 December 2021.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€63,229
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,515 of 24,148 companies
23.2
score / 100
Value12
Quality34
FCF yld-30%
Earn yld-131%
EV/EBITDA17.2x
ROE·
Gross mgn81%
Net mgn-20%
Debt/EBITDA15.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$0.12
Analyst consensus
Income statement
RevenueUS$16M
Gross profitUS$12.9M81% margin
EBITDAUS$1.7M11% margin
Net income-US$3.1M-15.0% margin
Valuation
Beta1.15
Balance sheet & cash
Market capUS$2.4M
Total debtUS$27.1M
Free Cash Flow-US$719k
Profitability & ownership
ROA17.5%
% insiders1.2%
% institutions3.0%
Last declaration on 6 December 2021
Declarations4 total
54,348 shares0Common StockSEC:0001493152-21-030567:0
27,174 shares0Common StockSEC:0001493152-21-030377:0
17,228 shares@ US$3.083372.7% of flowCommon StockSEC:0001493152-21-025255:0
6,246 shares@ US$3.269527.3% of flowCommon StockSEC:0001493152-21-024126:0
4 of 4 declarations
About Biotricity Inc.
Biotricity Inc. (ticker BTCY) is a U.S.-listed medical technology company traded on the NASDAQ market in the United States. Headquartered in Redwood City, California, the company was incorporated in 2012 and has evolved into a remote biometrics and digital diagnostics platform focused on chronic-condition monitoring, especially in cardiac care. Its business model is built around Technology-as-a-Service (TaaS), combining medical devices, software, recurring service fees, and data analytics rather than relying solely on one-time hardware sales.
Biotricity’s core business centers on cardiac monitoring and remote diagnostic solutions. The company develops and commercializes ECG monitoring devices and related digital health applications that enable physicians to monitor patients remotely and support diagnosis and post-diagnostic care. Its product portfolio has included Bioflux, Biotres, Bioheart, and more recently the cellular Biocore Pro, which management has described as a flagship technology. This product mix reflects a strategy aimed at creating a connected care ecosystem for clinicians and patients, with recurring revenue increasingly tied to software-like Technology Fees and service subscriptions.
Read moreShow less
From a competitive standpoint, Biotricity operates in the attractive but crowded remote patient monitoring and cardiac diagnostics market. The company differentiates itself through a focused specialty in cardiovascular disease, a platform-oriented offering, and its emphasis on workflow automation, AI-enabled enhancements, and operational efficiency. Its solutions are designed to help cardiologists, electrophysiologists, and other healthcare professionals improve patient compliance, detect issues earlier, and manage chronic conditions more efficiently. In that sense, Biotricity is positioned as a niche digital health player rather than a broad-based medtech conglomerate.
Geographically, the company is primarily U.S.-based, with its principal operating presence in California. Its commercial footprint is concentrated in the United States, though the addressable market it targets is broader and tied to the global trend toward connected, data-driven healthcare. Recent corporate updates have emphasized revenue growth, margin expansion, improving EBITDA, and operational progress, suggesting that the company is moving toward a more scalable business profile.
Recent developments have been notable. In 2025 and 2026, Biotricity reported stronger quarterly performance, including higher revenue, improved margins, and expanding EBITDA, while continuing to communicate a more disciplined cost structure. The company also announced investor presentation activity in May 2026, signaling continued capital markets engagement. For investors, BTCY remains a small-cap healthcare technology name with a differentiated remote cardiac monitoring franchise, but it still carries the typical risks of early-stage commercialization, competitive intensity, and execution dependence.
